I think so. New product development pipeline looks very impressive. CSL112 to treat with HDL increases for heart attack victims looks very advance in its process to get approval. CSL deserves higher PE due to high R&D expense of $1.2B will provide future results like CSL112. The other way to look at is if it reduces R&D by 40%, PE will be low twenties on future 3 year earnings .
I think so. New product development pipeline looks very...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.00 |
Change
2.260(0.78%) |
Mkt cap ! $141.5B | |||
| Open | High | Low | Value | Volume |
| $294.00 | $294.75 | $290.82 | $491.6M | 1.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8192 | $292.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.06 | 12368 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CSL (ASX) Chart |